Mackenzie Financial Corp Acquires 212,721 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mackenzie Financial Corp boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 4,907.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 217,056 shares of the medical equipment provider's stock after purchasing an additional 212,721 shares during the quarter. Mackenzie Financial Corp owned about 0.31% of Lantheus worth $19,418,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LNTH. Kestra Investment Management LLC acquired a new stake in shares of Lantheus during the 4th quarter worth approximately $27,000. Summit Securities Group LLC acquired a new stake in Lantheus during the 4th quarter worth $37,000. Parkside Financial Bank & Trust grew its holdings in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after acquiring an additional 280 shares during the period. 1620 Investment Advisors Inc. bought a new stake in shares of Lantheus during the 4th quarter valued at $125,000. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Lantheus during the 4th quarter valued at $136,000. 99.06% of the stock is owned by institutional investors.

Insider Buying and Selling at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 63,109 shares of company stock valued at $6,016,046. 2.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LNTH has been the topic of several recent research reports. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, Truist Financial lowered their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Lantheus has an average rating of "Buy" and an average target price of $132.67.

Lantheus Stock Performance

LNTH stock traded down $0.01 during midday trading on Friday, hitting $75.51. 987,971 shares of the company's stock were exchanged, compared to its average volume of 992,221. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89. The company has a market cap of $5.22 billion, a PE ratio of 12.56 and a beta of 0.23. The stock's fifty day moving average price is $92.07 and its 200-day moving average price is $91.73.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period in the prior year, the business earned $1.69 EPS. The company's revenue for the quarter was up .8% compared to the same quarter last year. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.